# Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

> **NCT06180863** · PHASE2 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** oral azacitidine (CC-486)

## Key facts

- **NCT ID:** NCT06180863
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-11
- **Primary completion:** 2028-11
- **Final completion:** 2029-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding.
- **Last updated:** 2023-12-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180863, "Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06180863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*